NCT06378190 2026-04-16
TranspoCART19
Instituto de Investigación Biomédica de Salamanca
Phase 1/2 Recruiting
Clinical Trials
63 trialsNCT04491370 2026-04-15
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
New York Medical College
Phase 1/2 Recruiting
NCT06767956 2026-04-13
Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
University of Pittsburgh
Phase 1/2 Withdrawn
NCT07319676 2026-04-09
Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas
National University Hospital, Singapore
Phase 1/2 Recruiting
NCT07506668 2026-04-02
RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
Affiliated Hospital of Nantong University
Phase 1/2 Not yet recruiting
NCT07508605 2026-04-02
CAR/TRuC-T
Shenzhen University General Hospital
Phase 1/2 Recruiting
NCT05702853 2026-03-27
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Medical University of South Carolina
Phase 1/2 Recruiting
NCT05092451 2026-03-18
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07283679 2026-02-24
Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Not yet recruiting
NCT03277729 2026-01-05
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Fred Hutchinson Cancer Center
Phase 1/2 Active not recruiting
NCT06464185 2025-11-18
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Active not recruiting
NCT04257578 2025-10-08
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
University of Washington
Phase 1/2 Active not recruiting
NCT04074746 2025-09-30
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03147885 2025-09-29
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Active not recruiting
NCT04697940 2025-09-19
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL
Chinese PLA General Hospital
Phase 1/2 Active not recruiting
NCT06213636 2025-08-06
BAH241
Essen Biotech
Phase 1/2 Recruiting
NCT07097207 2025-07-31
CAR-T
Shenzhen University General Hospital
Phase 1/2 Recruiting
NCT06045910 2025-07-28
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
Cancer Research UK
Phase 1/2 Recruiting
NCT07009002 2025-06-25
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT06987916 2025-06-05
Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma
Shanghai Tongji Hospital, Tongji University School of Medicine
Phase 1/2 Recruiting
NCT03114865 2025-05-22
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Active not recruiting
NCT04544592 2025-05-04
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
University of Colorado, Denver
Phase 1/2 Recruiting
NCT01458366 2025-04-30
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide
Thomas Jefferson University
Phase 1/2 Completed
NCT01701986 2025-02-28
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT06834529 2025-02-19
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences
Phase 1/2 Recruiting
NCT03307746 2024-12-02
RiVa
University Hospital Southampton NHS Foundation Trust
Phase 1/2 Completed
NCT05936229 2024-07-12
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Fred Hutchinson Cancer Center
Phase 1/2 Withdrawn
NCT02628405 2024-07-01
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
Academic and Community Cancer Research United
Phase 1/2 Active not recruiting
NCT06002659 2024-05-09
CARMA-01
Uppsala University
Phase 1/2 Recruiting
NCT03098355 2024-03-18
Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
Zhujiang Hospital
Phase 1/2 Withdrawn
NCT05613348 2024-03-18
CAR19T2
Zhujiang Hospital
Phase 1/2 Withdrawn
NCT04715217 2023-12-29
Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma
Shanxi Province Cancer Hospital
Phase 1/2 Unknown
NCT05932173 2023-07-11
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2 Unknown
NCT05771883 2023-05-24
A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1/2 Unknown
NCT05842707 2023-05-06
Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
Shanghai Tongji Hospital, Tongji University School of Medicine
Phase 1/2 Recruiting
NCT05776407 2023-03-20
Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma
Chongqing University Cancer Hospital
Phase 1/2 Unknown
NCT05570188 2022-11-30
Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies
Kunming Hope of Health Hospital
Phase 1/2 Withdrawn
NCT02898259 2022-09-26
Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Case Comprehensive Cancer Center
Phase 1/2 Terminated
NCT03704714 2022-08-15
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
Northwestern University
Phase 1/2 Suspended
NCT02481310 2022-02-21
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
Phase 1/2 Unknown
NCT02933320 2021-07-08
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
Cancer Research UK
Phase 1/2 Completed
NCT04747093 2021-02-10
Induced-T Cell Like NK Cells for B Cell Malignancies
Nanfang Hospital, Southern Medical University
Phase 1/2 Unknown
NCT04723914 2021-01-26
CAR-T
Shenzhen University General Hospital
Phase 1/2 Unknown
NCT01921387 2020-08-04
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT02547948 2020-07-16
CD19-targeting CAR T Cells for B Cell Lymphoma
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Withdrawn
NCT04429438 2020-06-12
Multi-CAR-T Cells Targeting B Cell Lymphomas
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Unknown
NCT01626495 2020-03-23
Pedi CART19
University of Pennsylvania
Phase 1/2 Completed
NCT01788189 2020-02-26
LeMLAR
University Hospital, Essen
Phase 1/2 Completed
NCT00294632 2020-02-24
Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03579927 2020-01-29
CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn